Close Menu

NEW YORK – Ann Arbor, Michigan-based Strata Oncology on Thursday announced that it has entered into a partnership with Mirati Therapeutics to identify and enroll patients with KRAS GI12C mutations into Mirati's Phase I/II study of MRTX849 as a treatment for patients with advanced solid tumors.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.